Mechanistically, we speculate that ADT-resistant clonal evolution can rapidly occur; therefore, matched tissue and/or blood-based biopsies sampled at more finite intervals, along with RNA analysis for AR splicing and transcriptional changes, if available, may inform us of the dynamic selection of resistant subclones and patients who were not explained solely by bulk tumor biopsies. This evidence concerns the gene AR and neoplasm.